SACHI BIOWORKS, INC.
SBIR Phase III award from National Aeronautics and Space Administration.
Summary
Sachi Bioworks received $3.59 million from NASA for a Phase III SBIR project to develop rapid, low-cost drug discovery using nanooligomers in space. The effort advances earlier research toward practical pharmaceutical applications in microgravity.
- Amount
- $3,595,236
- Agency
- National Aeronautics and Space Administration · National Aeronautics and Space Administration
- Program / Phase
- SBIR · Phase III
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CO
- Period
- 2023-07-10 → 2028-07-19
Technology domains
Space & Satellite Human Performance & Medical
Description
E014042 SBIR PHASE III RAPID, LOW-COST NANOLIGOMERTM BASED DRUG-DISCOVERY IN SPACE